Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).

被引：0
|
作者：
Dmoszynska, A.
Fetni, R.
Wang, Y.
Belkaci, M.
Sirard, C.
Goldberg, M.
Mayer, J.
Robak, T.
Skotnicki, A.
Hillmen, P.
机构：
[1] Med Univ Lublin, Lublin, Poland
[2] Univ Montreal, Montreal, PQ H3C 3J7, Canada
[3] CIRION Biopharma Res Inc, Montreal, PQ, Canada
[4] Genzyme, Boston, MA USA
[5] Univ Hosp, Brno, Czech Republic
[6] Kopernik Mem Hosp, Lodz, Poland
[7] Jagiellonian Univ Collegium, Krakow, Poland
[8] Gen Infirm, Leeds LS1 3EX, W Yorkshire, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：361S / 361S
页数：1
相关论文
共 50 条
  • [1] Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Hillmen, P.
    Skotnicki, A.
    Robak, T.
    Jaksic, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 339S - 339S
  • [2] Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Robak, T
    Skotnicki, AB
    Mayer, J
    Vukovic, V
    Weitman, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 573S - 573S
  • [3] Alemtuzumab (CAMPATH®,MABCAMPATH®) has superior progression free survival (PFS) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Hillmen, Peter
    Skotnicki, Aleksander
    Robak, Tadeusz
    Jaksic, Branimir
    Sirard, Cynthia
    Mayer, Jiri
    [J]. BLOOD, 2006, 108 (11) : 93A - 93A
  • [4] Progression free survival is superior with alemtuzumab vs chlorambucil as front-line therapy for patients with B-cell chronic lymphocytic leukemia
    Hillmen, P.
    Skotnicki, A.
    Robak, T.
    Jaksic, B.
    Sirard, C.
    Mayer, J.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 45 - 46
  • [5] Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-cell chronic lymphocytic leukemia.
    Hillmen, P
    Skotnicki, AB
    Robak, T
    Mayer, J
    Jaksic, B
    Vukovic, V
    Weitman, S
    [J]. BLOOD, 2004, 104 (11) : 687A - 687A
  • [6] Phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (CAMPATH®, MABCAMPATH®) vs. chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia (CAM307).
    Skotnicki, AB
    Robak, T
    Mayer, J
    Craig, A
    Weitman, S
    [J]. BLOOD, 2003, 102 (11) : 439A - 439A
  • [7] Incidence of genomic aberrations and associated efficacy from a phase III study comparing alemtuzumab (CAMPATH®, MABCAMPATH®) vs chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (BCLL).
    Robak, Tadeusz
    Dmoszynska, Anna
    Fetni, Raouf
    Wang, Ying
    Belkacz, Malika
    Sirard, Cynthia
    Goldberg, Mark
    Skotnicki, Aleksander
    Mayer, Jiri
    Hillmen, Peter
    [J]. BLOOD, 2006, 108 (11) : 593A - 593A
  • [8] Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia
    Mabed, M
    Aref, S
    Fouda, M
    El-Sharawy, S
    [J]. LEUKEMIA & LYMPHOMA, 2004, 45 (10) : 2029 - 2035
  • [9] Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chlorambucil as first-line therapy for B-cell chronic lymphocytic leukemia (BCLL)
    Mayer, J.
    Robak, T.
    Skotnicki, A.
    Jaksic, B.
    Dmoszynska, A.
    Sirard, C.
    Hillmen, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] FRONT-LINE THERAPY WITH CHLORAMBUCIL PLUS RITUXIMAB IN ELDERLY AND/OR UNFIT PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA
    Innocenti, I.
    Tarnani, M.
    Vannata, B.
    De Padua, L.
    Santini, F.
    Marietti, S.
    Za, T.
    Bellesi, S.
    Autore, F.
    Chiusolo, P.
    Sora, F.
    Sica, S.
    Leone, G.
    Laurenti, L.
    [J]. HAEMATOLOGICA, 2012, 97 : 523 - 524
12345